| Global epidemiology of dyslipidaemias A Pirillo, M Casula, E Olmastroni, GD Norata, AL Catapano Nature Reviews Cardiology 18 (10), 689-700, 2021 | 626 | 2021 |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ... The Lancet 398 (10312), 1713-1725, 2021 | 244 | 2021 |
| Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies E Olmastroni, G Molari, N De Beni, O Colpani, F Galimberti, M Gazzotti, ... European journal of preventive cardiology 29 (5), 804-814, 2022 | 131 | 2022 |
| Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of … M Casula, E Olmastroni, M Gazzotti, F Galimberti, A Zambon, ... Pharmacological Research 160, 105060, 2020 | 56 | 2020 |
| Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study M Casula, E Olmastroni, A Pirillo, AL Catapano, M Arca, M Averna, ... Atherosclerosis 277, 413-418, 2018 | 56 | 2018 |
| Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials M Casula, E Olmastroni, MT Boccalari, E Tragni, A Pirillo, AL Catapano Pharmacological research 143, 143-150, 2019 | 45 | 2019 |
| Adherence to the Mediterranean diet: impact of geographical location of the observations E Mattavelli, E Olmastroni, D Bonofiglio, AL Catapano, A Baragetti, ... Nutrients 14 (10), 2040, 2022 | 43 | 2022 |
| Impact of COVID-19 pandemic on adherence to chronic therapies: a systematic review E Olmastroni, F Galimberti, E Tragni, AL Catapano, M Casula International journal of environmental research and public health 20 (5), 3825, 2023 | 39 | 2023 |
| Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies E Olmastroni, MT Boccalari, E Tragni, F Rea, L Merlino, G Corrao, ... Pharmacological Research 155, 104514, 2020 | 35 | 2020 |
| Multilevel models to estimate carotid intima-media thickness curves for individual cardiovascular risk evaluation E Olmastroni, A Baragetti, M Casula, L Grigore, F Pellegatta, A Pirillo, ... Stroke 50 (7), 1758-1765, 2019 | 30 | 2019 |
| Gut microbiota functional dysbiosis relates to individual diet in subclinical carotid atherosclerosis A Baragetti, M Severgnini, E Olmastroni, CC Dioguardi, E Mattavelli, ... Nutrients 13 (2), 304, 2021 | 29 | 2021 |
| Proprotein convertase subtilisin-kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps A Baragetti, D Grejtakova, M Casula, E Olmastroni, GS Jotti, GD Norata, ... Pharmacological research 130, 1-11, 2018 | 27 | 2018 |
| Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study KI Dharmayat, AJ Vallejo-Vaz, CAT Stevens, JM Brandts, ARM Lyons, ... The Lancet 403 (10421), 55-66, 2024 | 24 | 2024 |
| Twelve variants polygenic score for low‐density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with … E Olmastroni, M Gazzotti, M Arca, M Averna, A Pirillo, AL Catapano, ... Journal of the American Heart Association 11 (7), e023668, 2022 | 20 | 2022 |
| Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials S Xie, F Galimberti, E Olmastroni, TF Luscher, S Carugo, AL Catapano, ... Cardiovascular research 120 (4), 333-344, 2024 | 17 | 2024 |
| Evaluation of lipoprotein (a) in the prevention and management of atherosclerotic cardiovascular disease: a survey among the Lipid Clinics Network AL Catapano, L Tokgözoğlu, M Banach, M Gazzotti, E Olmastroni, ... Atherosclerosis 370, 5-11, 2023 | 17 | 2023 |
| Lipoprotein (a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group C Pederiva, ME Capra, G Biasucci, G Banderali, E Fabrizi, M Gazzotti, ... Atherosclerosis 349, 233-239, 2022 | 17 | 2022 |
| How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia M Gazzotti, M Casula, E Olmastroni, M Averna, M Arca, AL Catapano Atherosclerosis Supplements 42, e35-e40, 2020 | 17 | 2020 |
| Geographical variation in medication prescriptions: a multiregional drug-utilization study V Russo, V Orlando, VM Monetti, F Galimberti, M Casula, E Olmastroni, ... Frontiers in pharmacology 11, 418, 2020 | 15 | 2020 |
| Lipoprotein (a) genotype influences the clinical diagnosis of familial hypercholesterolemia E Olmastroni, M Gazzotti, M Averna, M Arca, P Tarugi, S Calandra, ... Journal of the American Heart Association 12 (10), e029223, 2023 | 14 | 2023 |